Circulating Biomarkers: Additional Evidence Supporting Their Clinical Use in Breast Cancer
Decision brief
Answer first · skim in under a minute
Recent studies provide additional evidence supporting the clinical use of circulating biomarkers in breast cancer, including circulating tumor cells and ctDNA. This analysis reviews the key findings and their implications for pharma teams, investors, and analysts.
Circulating biomarkers in breast cancer now rest on more than metastatic companion diagnostics. Systematic reviews of early-stage liquid biopsy and FDA-cleared ctDNA assays give pharma and investors a clearer map of where blood-based testing already changes therapy decisions — and where it remains prognostic only.
Contents9 sections
Key Takeaways
- A Frontiers in Oncology systematic review catalogues circulating tumor cells and ctDNA uses in early-stage breast cancer tumor-microenvironment and detection contexts.
- Meta-analytic evidence links ctDNA positivity in early breast cancer to markedly worse disease-free survival (pooled HR about 6.92 in one 18-study synthesis of 1,670 patients).
- FDA-cleared plasma assays already guide ESR1- and PIK3CA-directed therapy choices in metastatic disease.
- Interventional proof that early-stage ctDNA-guided treatment switching improves overall survival is still incomplete.
What does the early-stage circulating biomarker literature show?
Qiu and colleagues published an open-access systematic review in Frontiers in Oncology that surveys circulating biomarkers in early breast cancer, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
The review is available on PMC10628786 and focuses on tumor-microenvironment biology, detection methods, and clinical development status beyond the metastatic setting.
For BD and diagnostics teams, that paper is a landscape map rather than a single pivotal trial: it organizes why liquid biopsy is being pushed earlier in the care continuum.
How strong is the prognostic signal for ctDNA in early breast cancer?
A systematic review and meta-analysis of prospective early or locally advanced non-metastatic breast cancer studies pooled 18 studies and 1,670 patients.
ctDNA positivity associated with shorter disease-free survival (pooled hazard ratio 6.92, 95% CI 3.64–13.13). Neoadjuvant and adjuvant subgroups also showed elevated recurrence risk when ctDNA remained detectable.
Real-world neoadjuvant cohorts using tumor-informed assays report high baseline detection (for example, 77.2% at baseline in one longitudinal evaluation indexed on PubMed 39984446), with mid-treatment persistence tied to recurrence risk and postoperative positivity showing high positive predictive value for relapse in that dataset.
Where are circulating biomarkers already therapy-guiding?
In metastatic hormone receptor–positive, HER2-negative disease, ctDNA assays detect ESR1 mutations that can appear under aromatase inhibitor pressure.
A npj Precision Oncology review summarizes FDA companion diagnostic uses, including Guardant360 CDx for ESR1 mutations relevant to elacestrant selection and the Qiagen therascreen PIK3CA RGQ PCR Kit for plasma PIK3CA testing tied to alpelisib eligibility.
Those clearances are the hard commercial proof points for liquid biopsy revenue today. Early-stage MRD monitoring is the growth thesis, not yet the same regulatory category.
What should pharma and investor teams monitor next?
Trials that switch therapy on molecular progression before radiographic progression — building on PADA-1 and SERENA-6 style ESR1-guided strategies — will determine whether ctDNA becomes a treatment-trigger biomarker rather than a risk label.
Assay analytical sensitivity below 0.01% variant allele frequency matters for early disease, where tumor DNA shed is low. Sponsors should demand tumor-informed versus tumor-agnostic performance data before locking companion-diagnostic deals.
European guideline bodies and reimbursement authorities will also decide whether early ctDNA surveillance is standard of care or remains trial-only, which directly affects kit utilization forecasts.
For pipeline teams, circulating biomarkers change trial design more than they change first commercial labels. Enrichment on detectable ctDNA can shrink sample size for adjuvant escalation studies, but false negatives from low-sensitivity assays can bias endpoints toward the null.
Investors comparing liquid-biopsy platforms should separate metastatic companion-diagnostic cash flows — already tied to elacestrant and PIK3CA pathways — from early-stage MRD optionality that still depends on interventional outcome wins in 2026–2028 readouts.
What remains unproven?
Strong DFS associations do not automatically prove that escalating therapy on a positive early-stage ctDNA result improves overall survival or quality of life versus standard imaging follow-up.
Heterogeneity across assays (I² near 80% in some meta-analyses) means pooled hazard ratios should not be treated as a universal clinical cut-off for any single commercial test.
The Frontiers review itself catalogues detection methods and clinical developments without asserting that every early-stage CTC or ctDNA assay is ready for population screening. Claims of population-level mortality reduction from routine liquid biopsy in asymptomatic women remain outside the evidence base cited here.
Related NovaPharma coverage
- Hayes ESMO breast cancer award 2026
- Data harmonization in AI clinical research
- Breast cancer disease profile
Frequently Asked Questions
What evidence supports circulating biomarkers in early breast cancer?
A Frontiers in Oncology systematic review (PMC10628786) maps circulating tumor cells and ctDNA in early-stage breast cancer. Separate meta-analyses associate ctDNA positivity with substantially worse disease-free survival, including pooled hazard ratios near 6.9 in early disease cohorts.
Which circulating biomarker tests are FDA-cleared for breast cancer therapy selection?
FDA-cleared companion diagnostics include Guardant360 CDx for ESR1 mutations guiding elacestrant eligibility and the therascreen PIK3CA RGQ PCR Kit for PIK3CA mutations relevant to alpelisib selection in appropriate metastatic settings.
What remains unproven about liquid biopsy in early breast cancer?
Prognostic associations are strong, but large interventional trials are still needed to prove that acting on early-stage ctDNA results improves overall survival versus imaging-guided care alone. Assay sensitivity and standardization also remain active constraints.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…